Liver transplantation for hepatocellular carcinoma

Cancer Journal

Volumn 14, Issue 2, 2008, Pages 95-99

  Heimbach, Julie K ^a,b  

^a Mayo Clinic   (United States)

^b MAYO CLINIC   (United States)

Author keywords

HCC recurrence; Hepatocellular carcinoma; Liver transplantation; MELD

Indexed keywords

CALCINEURIN INHIBITOR; CYCLOSPORIN; INTERLEUKIN 2 RECEPTOR ANTIBODY; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; OKT 3; PREDNISONE; RAPAMYCIN; TACROLIMUS; THYMOCYTE ANTIBODY; IMMUNOSUPPRESSIVE AGENT;

CANCER ADJUVANT THERAPY; CANCER GROWTH; CANCER PATIENT; CANCER STAGING; CANCER SURGERY; CANCER SURVIVAL; CHEMOEMBOLIZATION; DISEASE COURSE; GRAFT SURVIVAL; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; LIVER CELL CARCINOMA; LIVER GRAFT REJECTION; LIVER TRANSPLANTATION; LOW DRUG DOSE; OUTCOME ASSESSMENT; PATIENT SELECTION; PRIORITY JOURNAL; RADIOFREQUENCY ABLATION; RECURRENT CANCER; REVIEW; TUMOR GROWTH; TUMOR VOLUME; UNITED STATES; ADJUVANT THERAPY; ARTICLE; LIVER TUMOR; MORTALITY; RECURRENT DISEASE; VIRUS HEPATITIS;

CARCINOMA, HEPATOCELLULAR; HEPATITIS, VIRAL, HUMAN; HUMANS; IMMUNOSUPPRESSION; IMMUNOSUPPRESSIVE AGENTS; LIVER NEOPLASMS; LIVER TRANSPLANTATION; NEOADJUVANT THERAPY; RECURRENCE;

EID: 50949125781     PISSN: 15289117     EISSN: 1540336X     Source Type: Journal    
DOI: 10.1097/PPO.0b013e31816a0f6f     Document Type: Review

References (47)

1. Parkin DM, Bray F, Ferlay J, et al. Global cancer statistics. CA Cancer J Clin. 2005;55:74-108.
2. El-Serag HB, Rudolph KL. Hepatocellular carcinoma: epidemiology and molecular carcinogenesis. Gastroenterology. 2007;132:2557-2576.
3. Iwatsuki S, Starzl TE, Sheahan DG, et al. Hepatic resection versus transplantation for hepatocellular carcinoma. Ann Surg. 1991;214:221-228.
4. Ringe B, Pichlmayr R, Wittekind C, et al. Surgical treatment of hepatocellular carcinoma: experience with liver resection and transplantation in 198 patients. World J Surg. 1991;15:270-285.
5. Fung J, Marsh W. The quandary over liver transplantation for hepatocellular carcinoma: the greater sin? Liver Transpl. 2002;8:775-777.
6. Mazzaferro V, Regalia E, Doci R, et al. Liver transplantation for the treatment of small hepatocellular carcinomas in patients with cirrhosis. N Engl J Med. 334:11:693-699.
7. Llovet JM, Bruix J, Fuster J, et al. Liver transplantation for small hepatocellular carcinoma: the tumor-node-metastasis classification does not have prognostic power. Hepatology. 1998;27:1572-1577.
8. Figueras J, Jaurrieta E, Valla C, et al. Survival after liver transplantation in cirrhotic patients with and without hepatocellular carcinoma: a comparative study. Hepatology. 1997;25:1485-1489.
9. Romani F, Belli LS, Rondinara GF, et al. The role of transplantation in small hepatocellular carcinoma complicating cirrhosis of the liver. J Am Coll Surg. 1994;178:379-384.
10. Wachs ME, Bak TE, Karrer FM, et al. Adult living donor liver transplantation using a right hepatic lobe. Transplantation. 1998;66:1313-1316.
11. Trotter JF, Wachs M, Trouillot T, et al. Evaluation of 100 patients for living donor liver transplantation. Liver Transpl. 2006:290-195.
12. Sharma P, Balan V, Hernandez JL, et al. Liver transplantation for hepatocellular carcinoma: the MELD impact. Liver Transpl. 2004;10: 36-41.
13. Sharma P, Harper AM, Hernandez JL, et al. Reduced priority MELD score for hepatocellular carcinoma does not adversely impact candidate survival awaiting liver transplantation. Am J Transpl. 2006;6:1957-1962.
14. Freeman RB, Edwards EB, Harper AM. Waiting list removal rates among patients with chronic and malignant liver diseases. Am J Transpl. 2006;6:1416-1421.
15. Shetty K, Timmins K, Brensinger C, et al. Liver transplantation for hepatocellular carcinoma validation of present selection criteria in predicting outcome. Liver Transpl. 2004;10:911-918.
16. Island ER, Pomposelli J, Pomfret EA, et al. Twenty-year experience with liver transplantation for hepatocellular carcinoma. Arch Surg. 2005;140:353-358.
17. Zavaglia C, De Carlis L, Alberto AB, et al. Predictors of long-term survival after liver transplantation for hepatocellular carcinoma. Am J Gastroenterol. 2005;100:2708-2716.
18. Zimmerman MA, Trotter JF, Wachs M, et al. Predictors of long-term outcome following liver transplantation for hepatocellular carcinoma: a single center experience. J Eur Soc Organ Transpl. 2007;20:747-753.
19. Duffy JP, Vardanian A, Benjamin E, et al. Liver transplantation criteria for hepatocellular carcinoma should be expanded: a 22-year experience with 467 patients at UCLA. Ann Surg. 2007;246:502-511.
20. Leung JY, Zhu AX, Gordon FD, et al. Liver transplantation outcomes for early-stage hepatocellular carcinoma: results of a multicenter study. Liver Transpl. 2004;10:1343-1354.
21. 2006 Annual Report of the U.S. Organ Procurement and Transplantation Network and the Scientific Registry of Transplant Recipients: Transplant Data 1996-2005. Rockville, MD: Health Resources and Services Administration, Healthcare Systems Bureau, Division of Transplantation; 2006.
22. Wiesner RH, McDiamid SV, Kamath PS, et al. MELD and PELD: application of survival models to liver allocation. Liver Transpl. 2001 7:567-580.
23. Kamath P, Kim WR. The model for end-stage liver disease (MELD). Hepatology. 2007;45:797-805.
24. Wiesner RH, Freeman RB, Mulligan DC. Liver transplantation policy for hepatocellular cancer: the impact of the MELD allocation policy. Gastroenterology. 127(5 suppl 1):S261-S267.
25. Yao FY, Ferrell L, Bass NM, et al. Liver transplantation for hepatocellular carcinoma: expansion of the tumor size limits does not adversely impact survival. Hepatology. 2001;33:1394-1403.
26. Yao FY, Xiao L, Bass NM, et al. Liver transplantation for hepatocellular carcinoma: validation of the UCSF-expanded criteria based on preoperative imaging. Am J Transpl. 2007;7:2587-2596.
27. Decaens T, Roudot-Thoraval F, Hadni-Bresson S, et al. Impact of UCSF criteria according to pre-and post-OLT tumor features: analysis of 479 patients listed for HCC with a short waiting time. Liver Transpl. 2006;12:1761-1769.
28. Schwartz M, Roayaie S, Uva P. Treatment of HCC in patients awaiting liver transplantation. Am J Transpl. 2007;7:1875-1881.
29. Chen MS, Li JQ, Zheng Y, et al. A prospective randomized trial comparing percutaneous local ablative therapy and partial hepatectomy for small hepatocellular carcinoma. Ann Surg. 2006;243:321-328.
30. Shiina S, Teratani T, Obi S, et al. A randomized controlled trial of radiofrequency ablation with ethanol injection for small hepatocellular carcinoma. Gastroenterology. 2005;129:122-130.
31. Lin SM, Lin CJ, Lin CC, et al. Radiofrequency ablation improves prognosis compared to ethanol injection for hepatocellular carcinoma ≤4cm. Gastroenterology. 2004;127:1714-1723.
32. Lo CM, Ngan H, Tso WK, et al. Randomized controlled trial of transarterial lipiodol chemoembolization for unresectable hepatocellular carcinoma. Hepatology. 2002;35:1164-1171.
33. Llovet JM, Real MI, Montana X, et al. Arterial embolization or chemoembolization versus symptomatic treatment in patients with unresectable hepatocellular carcinoma: a randomized controlled trial. Lancet. 2002; 359:1734-1739.
34. Mazzaferro V, Battiston C, Perone S, et al. Radiofrequency ablation of small hepatocellular carcinoma in cirrhotic patients awaiting liver transplantation: a prospective study. Ann Surg. 2004;240:900-909.
35. Lu DS, Yu NC, Raman SS, et al. Percutaneous radiofrequency ablation of small hepatocellular carcinoma as a bridge to liver transplantation. Hepatology. 2005;41:1130-1137.
36. Yao FY, Kinkhabwala M, LaBerge JM, et al. The impact of preoperative loco-regional therapy on outcome after liver transplantation for hepatocellular carcinoma. Am J Transplant. 2005;5:795-804.
37. Yao FY, Hirose R, LaBerge JM, et al. A prospective study on down-staging of hepatocellular carcinoma prior to liver transplantation. Liver Transpl. 2005;11:1505-1514.
38. Roayaie S, Frischer JS, Emre SH, et al. Long-term results with multi-modality adjuvant therapy and liver transplantation for the treatment of hepatocellular carcinomas larger than 5 cm. Ann Surg. 2002;235:533-539.
39. Decaens T, Roudot-Thoraval F, Bresson-Hadni S, et al. Role of immunosuppression and tumor differentiation in predicting recurrence after liver transplantation for hepatocellular carcinoma: a multicenter study of 412 patients. World J Gastroenterol. 2006;12:7319-7325.
40. Guba M, von Breitenbuch P, Steinbauer M et al. Rapamycin inhibits primary and metastatic tumor growth by anti-angioneogenesis: involvement of vascular endothelial growth factor. Nat Med. 2002;8:128-135.
41. Kauffman HM, Cherikh WS, Cheng Y, et al. Maintenance immunosuppression with TOR inhibitors is associated with a reduced incidence of de novo malignancies. Am J Transplant. 2005;80:883-889.
42. Toso C, Meeberg GA, Bigam DL, et al. De novo sirolimus-based immunosuppression after liver transplantation for hepatocellular carcinoma: long-term outcomes and side effects. Transplantation. 2007;83: 1162-1168.
43. Campbell MS, Rai J, Kozin E, et al. Effects of sirolimus vs. calcineurin inhibitors on renal dysfunction after orthotopic liver transplantation. Clin Transplant. 2007;12:377-384.
44. Kuo A, Terrault NA. Management of hepatitis C in liver transplant recipients. Am J Transplant. 2006;6:449-458.
45. Wong SN, Reddy KR, Keefe EB, et al. Comparison of clinical outcomes in chronic hepatitis B liver transplant candidates with and without hepatocellular carcinoma. Liver Transpl. 2007;13:334-342.
46. Melum E, Friman S, Bjoro K, et al. Hepatitis C impairs survival following liver transplantation irrespective of concomitant hepatocellular carcinoma. J Hepatol. 2007;47:777-783.
47. Bozorgzadeh A, Orloff M, Abt P. Survival outcomes in liver transplantation for hepatocellular carcinoma, comparing impact of hepatitis C versus other etiology of cirrhosis. Liver Transpl. 2007;13:807-813.